Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
James D Doecke, Larry Ward, Samantha C Burnham, Victor L Villemagne, Qiao-Xin Li, Steven Collins, Christopher J Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R Rainey-Smith, Ralph N Martins, Colin L Masters
ALZHEIMERS RESEARCH & THERAPY | BMC | Published : 2020
BACKGROUND: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. METHODS: Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD..View full abstract
Related Projects (1)
JDD received funding from CSIRO (AU). LW is funded by Cooperative Research Centre for Mental Health. SCB received funding from CSIRO (AU). SRRS is funded by the BrightFocus Foundation. The funding sources had no role in the study design, the collection, analyses, interpretation, writing of the report or the decision to submit the article for publication.